Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by tuesdaynightridon Jun 19, 2014 7:45am

238 Views

Post# 22674146

RE:RE:Rat model validation was next milestone/catalyst.

Regarding Gustoes Milestone 5 (securing agreement with big Pharma), depending on how quickly news is disseminated from Ph1/2, there may actually begin a bidding war in 2015.
Patent expiration and ineffective treatments to date means the shelves are bare at many Pharma.
This assumes they do start in 1st q 2015 and are able to identify and enroll 30 patients within say a 4-5 month time frame. It is also my understanding that these patients have localized bladder cancer...
not metastatic.

Hence my earlier question: how quickly is news allowed to be communicated in a ph1/2 trial when
there is no randomized population (ie all 30 patients receive the same treatment).
What are the rules?

Bullboard Posts

Thunder Gold makes generational discovery